Overview

Prevenar (13v) Infant Drug Use Investigation

Status:
Completed

Trial end date:
2016-05-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to investigate post marketing use and safety of Prevnar ( 13v) in infants vaccinated for the first time at the age of 2 months, inclusive, to 7 months, exclusive.

Details

Lead Sponsor:

Pfizer

Treatments:

Heptavalent Pneumococcal Conjugate Vaccine